Advanced Therapeutics Pharmaceutical Outsourcing Market Report 2026

The advanced therapeutics pharmaceutical outsourcing market size has grown steadily in recent years. It will grow from $8.41 billion in 2025 to $8.82 billion in 2026 at a compound annual growth rate (CAGR) of 5%. The growth in the historic period can be attributed to rising biologics pipeline, high cost of in-house manufacturing, increasing prevalence of oncology and rare diseases, lack of internal expertise in advanced therapies, globalization of clinical trials.

The advanced therapeutics pharmaceutical outsourcing market size is expected to see strong growth in the next few years. It will grow to $10.73 billion in 2030 at a compound annual growth rate (CAGR) of 5%. The growth in the forecast period can be attributed to growth in personalized medicine adoption, expansion of commercial-scale cell and gene therapies, increasing regulatory complexity, surge in biotech start-up funding, demand for faster time-to-market. Major trends in the forecast period include increasing outsourcing of cell and gene therapy manufacturing, rising demand for end-to-end cdmo services, expansion of specialized viral vector production capabilities, growing focus on regulatory and quality compliance support, accelerated clinical trial outsourcing for rare and complex indications.

The growing adoption of cell and gene therapies is expected to drive the expansion of the advanced therapeutics pharmaceutical outsourcing market in the coming years. Cell and gene therapies are cutting-edge treatments that utilize living cells or genetic material to treat or potentially cure diseases. Advanced therapeutics pharmaceutical outsourcing supports these therapies by providing access to providers with proven expertise and experienced personnel, helping companies save time and resources in building their in-house teams. For instance, in March 2024, IQVIA Holdings Inc., a US-based provider of advanced analytics, technology solutions, and clinical research services for the life sciences and healthcare sectors, reported that global spending on cell and gene therapies reached $5.9 billion in 2023, representing a 38% increase from 2022. Therefore, the rising adoption of cell and gene therapies is fueling growth in the advanced therapeutics pharmaceutical outsourcing market.

Major companies in the advanced therapeutics pharmaceutical outsourcing market are focusing on strategic partnerships to deliver dependable services to clients. A strategic partnership is a collaborative arrangement between two or more organizations formed to achieve mutually beneficial objectives that each partner could not accomplish alone. For instance, in January 2023, Lonza, a Switzerland-based manufacturer serving the pharmaceutical, biotechnology, and nutrition sectors, partnered with Context Therapeutics Inc., a US-based biopharmaceutical company developing medicines for solid tumors. Under the partnership, Lonza provides manufacturability assessment, gene and cell line construction, and process development for both drug substances and drug products.

In December 2023, Ajinomoto Co., Inc., a Japan-based provider of amino acids and biomanufacturing solutions, completed the acquisition of Forge Biologics Inc. for an undisclosed amount. Through this acquisition, Ajinomoto aims to strengthen its position in the gene therapy manufacturing market by expanding viral vector production capabilities, enhancing its CDMO service offerings, and accelerating innovation in advanced gene therapy development. Forge Biologics Inc. is a US-based gene therapy-focused CDMO specializing in adeno-associated virus manufacturing and comprehensive end-to-end development services.

Major companies operating in the advanced therapeutics pharmaceutical outsourcing market are Thermo Fisher Scientific Inc., Laboratory Corporation of America Holdings, IQVIA, ICON plc, SGS SA, Lonza Group, Parexel International Corporation, WuXi AppTec, Syneos Health, Catalent Inc., Charles River Laboratories International, Recipharm AB, Samsung Biologics, Vetter Pharma International GmbH, Medpace Holdings Inc., Fujifilm Diosynth Biotechnologies, AGC Biologics, Evotec SE, Piramal Pharma Solutions, Corden Pharma International LLC, Novotech Pty Ltd., Cytovance Biologics.

North America was the largest region in the advanced therapeutics pharmaceutical outsourcing market in 2025. The regions covered in the advanced therapeutics pharmaceutical outsourcing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the advanced therapeutics pharmaceutical outsourcing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the advanced therapeutics pharmaceutical outsourcing market by increasing the cost of importing critical raw materials such as viral vectors, single-use bioprocessing equipment, and analytical instruments used in cell and gene therapy development. These impacts are most pronounced across cdmo manufacturing services and analytical testing segments, particularly in North America and Europe, which rely heavily on cross-border supply chains. Asia-Pacific outsourcing hubs are also affected due to tariffs on specialized equipment sourced from the US and EU. However, tariffs have encouraged regional capacity expansion, local sourcing strategies, and long-term investments in domestic advanced therapy manufacturing infrastructure.

The advanced therapeutics pharmaceutical outsourcing market research report is one of a series of new reports that provides advanced therapeutics pharmaceutical outsourcing market statistics, including advanced therapeutics pharmaceutical outsourcing industry global market size, regional shares, competitors with a advanced therapeutics pharmaceutical outsourcing market share, detailed advanced therapeutics pharmaceutical outsourcing market segments, market trends and opportunities, and any further data you may need to thrive in the advanced therapeutics pharmaceutical outsourcing industry. This advanced therapeutics pharmaceutical outsourcing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Advanced therapeutic pharmaceutical outsourcing involves delegating specialized pharmaceutical services associated with advanced therapeutic products to external providers. These products typically include innovative therapies such as cell and gene therapies, personalized medicines, biologics, and other novel treatments. Such outsourcing is utilized to access specialized expertise and capabilities required for the development, testing, and manufacturing of advanced therapeutic products.

The primary services in advanced therapeutics pharmaceutical outsourcing include contract research organizations (CROs) and contract development and manufacturing organizations (CDMOs). Outsourcing services provided to CROs may encompass a variety of specialized solutions that support the development and commercialization of advanced therapeutic products. These services are applied across indications such as oncology, neurology, cardiology, infectious diseases, and others, and involve outsourcing cell therapy, gene therapy, and RNA-based therapies for preclinical services, clinical services, as well as commercial manufacturing and packaging applications.

The advanced therapeutics pharmaceutical outsourcing market includes revenues earned by entities by providing services such as research and development support, process development and manufacturing, comprehensive analytical testing and characterization, regulatory support, clinical manufacturing, commercial manufacturing, implementation of quality systems, consulting and strategic services. The market value includes the value of related goods sold by the service provider or included within the service offering.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.